SQZ Biotechnologies Company
SQZ was delisted on the 3rd of July, 2023.
53 hedge funds and large institutions have $76.6M invested in SQZ Biotechnologies Company in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 19 reducing their positions, and 6 closing their positions.
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
6% more funds holding
Funds holding: 50 → 53 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
42% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 19
45% less capital invested
Capital invested by funds: $139M → $76.6M (-$62.8M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $7K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$1.57M |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
+$1.11M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$429K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$326K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$180K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BP
BBR Partners
New York
|
-$657K |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$461K |
| 3 |
BlackRock
New York
|
-$206K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$178K |
| 5 |
RAM
Redmond Asset Management
Henrico,
Virginia
|
-$154K |
SQZ Hedge Fund Activity: Q1 2022 in Review
53 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in SQZ Biotechnologies Company (SQZ) for Q1 2022, worth a combined $76.6M — down 45% from $139M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new SQZ positions and 6 closed out — a net gain of 3 holders — while 11 added to existing stakes and 19 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $1.57M. The largest seller was BBR Partners, exiting entirely with an estimated $657K sold.
- 53 institutional investors held SQZ Biotechnologies Company (SQZ) as of Q1 2022, up from 50 in Q4 2021.
- Funds reported $76.6M of SQZ Biotechnologies Company stock for Q1 2022, down 45% quarter-over-quarter.
- 9 funds opened new SQZ Biotechnologies Company positions in Q1 2022 and 6 closed out, a net change of +3 holders.
- The largest SQZ Biotechnologies Company buyer in Q1 2022 was 683 Capital Management, an estimated $1.57M added.
- The largest SQZ Biotechnologies Company seller in Q1 2022 was BBR Partners, an estimated $657K sold.
Based on aggregated 13F filings for Q1 2022.